Stenocare has entered into an agreement to acquire all shares in Canngros from DanCann. The deal is expected to add annual revenues of approximately DKK 4-6 million, propelling the company towards it’s break even goal. BioStock contacted CEO Thomas Skovlund Schnegelsberg to learn more.
Read the full article at biostock.se:
https://biostock.se/en/2025/11/stenocare-forvarvar-canngros/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se